Lilly Wins Axid Patent Ruling; Ivax Directed To Pay Attorneys Fees

Ivax must pay Lilly's attorney fees after a court ruling found that its challenge of the Axid (nizatidine) chemical compound patent was not based on "reasonable and good faith" assumptions

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet